- Glargine-300 reduces nocturnal hypoglycemia and slightly improves glycemic control compared with glargine-100 in adults with type 1 diabetes (T1D) or type 2 diabetes (T2D).
Why this matters
- Basal insulins have significantly improved treatment of both T1D and T2D, but hypoglycemia remains a barrier to optimal glycemic control.
- Systematic review and meta-analysis of 9 studies comparing glargine-300 with glargine-100 in 3977 adults with T1D or T2D.
- Funding: None.
- Glargine-300 was significantly associated with less confirmed nocturnal hypoglycemia (pooled relative risk [RR], 0.81; 95% CI, 0.69-0.95) and clinically significant nocturnal hypoglycemia (RR, 0.75; 95% CI, 0.63-0.91).
- In subgroup analysis by diabetes type, glargine-300 was associated with less confirmed nocturnal hypoglycemia in T1D (RR, 0.64; 95% CI, 0.42-0.97).
- There was a decrease in HbA1c in favor of glargine-300 (effect size, −0.08; 95% CI, −0.14 to −0.01).
- Relative short duration of studies.
- Differences in injector devices across studies.
- Missing data on weight gain, increased insulin dose, or adverse events in some studies.
- Between-study heterogeneity in T1D studies regarding nocturnal hypoglycemia.